var data={"title":"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - E3","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - E3</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes-e3/contributors\" class=\"contributor contributor_credentials\">Lloyd Axelrod, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes-e3/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">ANSWER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Correct.</p><p>The patient needs more insulin. Assuming conservatively a dose requirement of 0.8 <span class=\"nowrap\">units/kg</span> for an obese patient with type 2 diabetes, the estimated dose requirement is 72 units per 24 hours for this patient.</p><p>Several weeks later, the patient returns. She is taking NPH 55 units before breakfast. The fasting glucose level is 135 to 145 <span class=\"nowrap\">mg/dL</span> (7.5 to 8.0 <span class=\"nowrap\">mmol/L)</span>. Premeal and bedtime glucose levels are 160 to 170 <span class=\"nowrap\">mg/dL</span> (8.9 to 9.4 <span class=\"nowrap\">mmol/L)</span>. The patient is again encouraged to increase the dose of NPH insulin before breakfast incrementally. When the dose is 75 units before breakfast, the fasting glucose value is usually 110 to 120 <span class=\"nowrap\">mg/dL</span> (6.1 to 6.7 <span class=\"nowrap\">mmol/L);</span> the premeal and bedtime glucose levels are usually 125 to 135 <span class=\"nowrap\">mg/dL</span> (6.9 to 7.5 <span class=\"nowrap\">mmol/L)</span>. Over the next three months, the glycated hemoglobin (A1C) value falls to 7.1 percent.</p><p>You stop the <a href=\"topic.htm?path=glipizide-drug-information\" class=\"drug drug_general\">glipizide</a> since the patient is on a full dose of exogenous insulin, and little or no benefit will accrue from stimulating endogenous insulin. You continue the <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a>, which the patient has tolerated well, to minimize weight gain and for its beneficial effects on hepatic glucose production and circulating lipid levels in patients with the metabolic syndrome.</p><p>Alternatively, you could have stopped the sulfonylurea (<a href=\"topic.htm?path=glipizide-drug-information\" class=\"drug drug_general\">glipizide</a>) when you initially added insulin. Some prefer this approach. However, the glucose levels may rise in the ensuing weeks until the dose of injected insulin is sufficient to achieve metabolic control. This may be disheartening to the patient and may on occasion cause or worsen symptoms of hyperglycemia. This approach should probably be limited to those settings where you or a qualified member of your staff (eg, a diabetes nurse educator) will be in frequent communication (every five days or so) with the patient to facilitate rapid increases in the dose of insulin and to address a rise in the glucose level if it occurs. This consultant prefers the approach used in this case study.</p><p>Good work.</p><p><strong>However, you discover in cross-coverage that your colleagues have treated similar patients differently with comparable results. To explore the consequences of the other actions, return to the case at the beginning of this sequence.</strong> (See <a href=\"topic.htm?path=interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes\" class=\"medical medical_review\">&quot;Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes&quot;</a>.)</p><p><strong>For additional information, see the comment at the end of this sequence.</strong> (See <a href=\"topic.htm?path=interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes-comment\" class=\"medical medical_answer\">&quot;Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes: Comment&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 4109 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1\" id=\"outline-link-H1\">ANSWER</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes\" class=\"medical medical_review\">Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-2-switching-from-oral-agents-to-insulin-in-type-2-diabetes-comment\" class=\"medical medical_answer\">Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes: Comment</a></li></ul></div></div>","javascript":null}